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(Sponsored by Michele Barry, Department of Medicine, Yale University School of Medicine, New Haven, 
CT.) 
 
The purpose of this study was to evaluate the epidemiology of Trypanosoma cruzi infection, to 
evaluate the TESA blot, and to characterize cardiac findings of patients with Chagas disease in a 
rural setting near Arequipa, Peru. The study site was the town of Quequeña, Peru with a 
population of 774 with 236 inhabitants under the age of 18 according to the 2005 census 
conducted by Peru. A fumigation/insect collection campaign was done in December of 2006 to 
quantify household infestation levels, document housing characteristics, and GPS household 
locations. Of the 602 people surveyed to be living in Quequeña, blood samples were taken from 
445 (73.9%), and 15 (3.37%) were positive for Chagas disease by ELISA and confirmed by 
immunofluorescence. The TESA blot was also performed on all positives (N=15) and a random 
subset of negative (N=20) blood samples with a sensitivity of 93% and a specificity of 100%. 
Electrocardiograms (EKGs) were performed on 37 people, 9 of whom were positive for Chagas 
disease and the other 28 were age and sex matched controls. All EKGs of Chagas positive 
patients were normal and 27 of 28 EKGs were normal in the control group. Of the 284 
households in Quequeña, 242 (85.2%) were sprayed, and fifty-eight (24.0%) were infested with 
triatomines. Nineteen households (7.85%) harbored triatomines infected with T. cruzi.  Of the 15 
patients positive for Chagas disease, 9 lived in a house positive for triatomines (60%), of which 3 
were positive for T. cruzi (33%). A serosurvey for Chagas disease in a rural community of Peru 
was successfully conducted with a prevalence of 3.4%. This information will aid the local Chagas 
Control Program in its estimates as it continues its fumigation campaign. In addition, the TESA 
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Chagas disease or American trypanosomiasis, is caused by the parasitic protozoa 
Trypanosoma cruzi and is transmitted by the insect vector belonging to the subfamily 
triatomine with a geographic range from the southern United States to Argentina.  About 
13 million people are estimated to be infected with T. cruzi with many more at risk for 
acquiring the disease.  Chagas disease can be transmitted four ways: by the blood sucking 
triatomine insect, congenital transmission, blood transfusion, and by ingesting 
contaminated agricultural products.  The disease disproportionately affects the rural poor 
as the triatomine vector is domiciliated, living in and around poorly constructed homes 
with cracks and holes.  Insecticide campaigns have proven effective in reducing the 
transmission of Chagas disease.  Of those infected about one third go on to develop 
serious irreversible damage to the heart or gastrointestinal tract.  Diagnosis in the acute 
phase relies on direct visualization of the parasite and the chronic phase relies on the 
detection of circulating antibodies to T. cruzi.  Treatment of persons infected with T. 
cruzi is often ineffective and inadequate with greatest treatment benefit seen in those 
recently infected. 
1.1 Parasite and Vector 
 Chagas disease is caused by the parasitic protozoa Trypanosoma cruzi, which is 
transmitted by the insect vector belonging to the subfamily Triatominae.  The other 
member of the genus Trypanosoma that causes human disease is Trypanosoma brucei, 
which causes African sleeping sickness in sub-Sahara Africa (1). 
 The life cycle of T. cruzi is divided into morphologically distinct stages 
depending on the host and tissue location.  Four stages are seen, two in the insect host 
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and two in the mammalian host.  Triatomine insects harbor the replicative epimastigotes 
and shed the infective metacylcic trypomastigotes.  Mammalian hosts contain the 
intracellularly replicative amastigotes and circulate in blood the trypomastigotes.  
Beginning with a blood meal from an infected mammalian source triatomine insects 
become infected with the trypomastigote form of T. cruzi.  Trypomastigotes are identified 
microscopically by their slender appearance and undulating membrane with the 
kinetoplast posterior to the nucleus (see Figure 1).  Kinetoplasts are interlocked DNA 
minicircles and maxicircles contained within the matrix of a single mitochondrion.  
Kinetoplast DNA (kDNA) is unique to trypanosomes and related protozoa with a 
structure that resembles chain mail and a singular form of replication (2, 3). Once in the 
midgut of the triatomine the trypomastigotes transform into epimastigotes which attach to 
the wall of the hindgut.  Epimastigotes are replicative and are distinguished from 
trypomatigotes by a shortened form and location of the kinetoplast anterior to the 
nucleus.  In the hindgut the epimastigote transforms into metacyclic trypomastigotes.  
Metacyclic trypomastigotes are the infective, non-replicative form, which are shed in 




Figure 1. This is a micrograph of Trypanosoma cruzi in a blood smear using Giemsa staining 
technique (courtesy of the Public Health Image Library, CDC, http://phil.cdc.gov/phil/home.asp). 
 
 T. cruzi are classified as stercoraria because of a unique vectorial fecal 
transmission (1).  Infection occurs when feces containing metacyclic trypomastigotes 
enter breaks in the skin caused by triatomine bite, micro abrasions secondary to 
scratching the bite, or mucous membranes (5).  It is unlikely that T. cruzi can penetrate 
intact skin.   
 T. cruzi can be further classified as type I or type II based on analysis of randomly 
amplified polymorphic DNA (RAPD), rRNA 24S subunit, rRNA promoter region, and a 
195 bp DNA repeat (6-9).  More recently the T. cruzi II lineage has been further 
subdivided by characterization of rRNA subunits and miniexons into five different 
classifications designated IIA through IIE (10).  There are some relevant clinical and 
epidemiological correlations relating to the classification into two broad groups.  Type II 
is commonly isolated from humans and appears to be associated more with the domestic 
cycle whereas Type I is more often found in the sylvatic cycle (11).  These two groups 
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also show a geographic distribution in human infection with Type I, which produces 
milder infections, more prevalent in Central America and northern South America, while 
type II, the more aggressive form, is more prevalent in South America.  The evolutionary 
adaptation for Type II to the domestic cycle may explain why the vast majority of 
seropositive humans are found to be infected with this lineage.  Interestingly, in an 
endemic zone of Bolivia both lineages were isolated from T. cruzi with almost the same 
frequency (0.67 and 0.66).  However, children infected in these zones were infected with 
a greater frequency by T. cruzi II than T. cruzi I, 0.85 and 0.19 respectively.  Clearly the 
role of T. cruzi II in the domestic cycle does not fully explain its predominace in human 
infection and it is postulated that specific host immunologic factors may be an important 
in controlling T. cruzi I infection (12). 
The vector responsible for spread of Chagas disease belongs in the order 
Hemiptera, family Reduviidae and the subfamily Triatominae.  There are over 130 
species of triatomine with only 3 synanthropic species important in human transmission: 
Triatoma infestans, Rhodnius prolixus, and Panstrongylus megistus (1, 5).  These three 
genera responsible for human transmission have a geographic range stretching from 
Mexico to Argentina.  The most important vector for transmission in South America is 
Triatoma infestans, see Figure 2, and in Central America, Colombia and Venezuela 
Rhodnius prolixus (13).  Transmission in Southern Peru is almost exclusively via T. 
infestans (14).   
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Triatomines are obligate hematophagous 
insects throughout their lifecycle.  After hatching, 
triatomines undergo five nymphal instars over the 
next six months before reaching the adult stage.  
Triatomines can fast for up to 200 days of their 
twelve to eighteen month lifespan but require blood 
meals in order to develop.  Triatomines are active at 
night with increased activity at dusk and dawn (14).  
It is at this time that they feed on their mammalian hosts (15).  In the wild T. cruzi can 
maintain its life cycle among over 130 species of Triatomine and over 100 species of 
mammals (16).  Humans are the important reservoirs among the domestic triatomine 
species with other domesticated animals playing a significant role.  Studies done in 
Argentina and Venezuela have noted the seropositivity of dogs and cats living in close 
proximity to humans as risk factors for Chagas disease (17-19).  It is notable that in the 
Andean regions of Peru and Bolivia guinea pigs and rabbits serve as important reservoirs 
of T. cruzi.  These animals, often used as a food source, are raised in the home or in 
peridomestic cages, see Figure 3. 
 





Figure 3.  Peridomestic guinea pig cages next to a porous rock wall in Quequeña, Peru.   The cracks 
in the rock wall as well as the homes are an ideal habitat for T. infestans. 
 
In the domestic setting, triatomines hide inside the dwelling in cracks and holes in 
the wall, thatched roofs, and behind hangings on the wall.  Outside the dwelling they 
occupy rock piles or rock fences and cages used for animal rearing.  It is from these 
locations that the triatomine emerge at night for a blood meal from humans and other 
domestic animals.  Often feces from the insect can be found streaked on walls and 
bedding in infected homes, see Figure 4. 
T. infestans is so adapted to its domestic role that it has difficulty surviving 
outside of this specialized niche. It is thought that the natural habitat for T. infestans is the 
Cochabamba valley of Bolivia because it is the only location in which sylvatic 
populations can be found in rock piles associated with wild populations of guinea pigs.  
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Introduction of this vector into human habitats might have occurred in association with 
pre-Columbian domestication of the guinea pig.  After adapting to a domestic 
environment, spread throughout South America is presumed to have occured via human 
migrations (20).  T. cruzi DNA has been isolated and amplified by PCR from 4000 year 
old mummies on the coast of Chile where T.infestans is strictly domestic (21).  This lends 
evidence to the theory of synanthropic co-migration of domesticated T. infestans from an 
original sylvatic source in Bolivia. 
 
Figure 4.  T. infestans excreta found on bed (left) and wall (right) of dwelling in Quequeña, Peru. 
 
1.2 Clinical Characteristics 
1.2.1 Pathophysiology 
 After successful inoculation into the mammalian host T. cruzi metacyclic 
trypomastigotes invade local tissues and proceed with obligate intracellular replication 
with subsequent local and disseminated invasion.  T. cruzi gains access to the 
intracellular compartment via membrane bound vacuoles.  Attachment of the parasites to 
the cells is glycoprotein receptor mediated.  This receptor mediated attachment activates 
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various calcium signaling pathways that induce reorganization of the cytoskeleton with 
lysosomal recruitment (22).  Lysosomal fusion with the parasite vacuole activates pH 
sensitive enzymes that release the invading parasite into the host cell cytoplasm (23).  
Once in the cytoplasm the trypomastigotes differentiate into amastigotes and 
approximately 20 hours later begin to replicate by binary fission with a doubling time of 
about 12 hours.  4-5 days later the host cell cytoplasm is full of replicative amastigotes 
and they differentiate back into trypomastigotes as the cell ruptures and spills 
approximately 500 parasites for each initial trypomatigote (24).  These newly released 
parasites invade local tissues and disseminate hematogenously throughout the body with 
a predilection for muscles especially myocardium. 
 Endomyocardial biopsies done on patients with acute Chagas disease show 
diffuse neutrophilic and monocytic inflammatory infiltrates with scarce fibrosis and 
occasional intracellular amastigote nests (25).  During the chronic phases of Chagas 
disease when parasitemia is no longer present endomyocardial biopsies reveal continued 
presence of the parasite as demonstrated by direct visualization of the parasite, 
immunofluorescent deposits, or PCR detection of T. cruzi DNA (26).  Histopathologic 
changes in chronic Chagas disease include myocardial necrosis, inflammatory infiltrates, 
and fibrosis.  Cadaveric studies show preferential fibrosis of the conducting pathways of 
the heart that affects the right bundle branch and the anterior division of the left bundle 
branch correlating well with premortem EKG findings (27).  Some have proposed a 
largely auto-immune process to explain the effects of Chagas disease while others note 
the presence of parasites in the tissues affected.  Although not understood completely, the 
pathogenesis of these lesions is thought to be due to chronic low grade infection coupled 
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with an adverse immunologic response by the host (28, 29).  Autonomic nervous system 
derangements and microvascular disturbances have also been proposed and contributing 
mechanisms. 
 Gastrointestinal involvement of Chagas disease presents as one of the 
megasyndromes.  The affected colon undergoes marked muscular hypertrophy with 
luminal dilation and uncoordinated peristalsis.  Histopathologic studies found that 
chronic Chagas patients with megacolon had significantly higher numbers of natural 
killer cells and cytotoxic lymphocytes within enteric ganglia compared with 
asymptomatic Chagas patients.  Megacolonic Chagas patients also displayed a 20% 
reduction in muscle innervation compared to asymptomatic Chagas patients and non-
Chagasic controls (30). 
 
1.2.2 Acute Chagas Disease 
 Acute Chagas disease occurs approximately one week after inoculation with T. 
cruzi.  When infection occurs through a break in the skin a characteristic chagoma may 
form, which is an area of local inflammation, induration, and erythema with occasional 
lymph node involvement (31).  When infection occurs through the conjunctiva, 
ispsilateral palpebral edema results in the classic sign of acute Chagas disease: Romañas 
sign, see Figure 5.  Acute infection is normally seen only in children but can occur at any 
age.  Systemic manifestations of acute infection are usually non-specific and easily 
misdiagnosed such as fever, malaise, lymphadenopathy and hepatosplenomegaly.  These 
symptoms improve over the ensuing 6-8 weeks with complete resolution in most cases.  
In children, or immunosuppressed patients, some cases of acute Chagas disease can be 
quite severe with myocarditis or meningoencephalitis that may result in death (32, 33).  
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The large majority of acute Chagas disease cases go undiagnosed and untreated 
presumably because of mild symptoms.  However, poor access to health care and diffuse 
non-specific symptoms are also important factors to consider. 
 
 
Figure 5. This child from Panama is suffering from Chagas disease manifested as an acute infection 
with swelling of the right eye (courtesy of the Public Health Image Library, CDC, 
http://phil.cdc.gov/phil/home.asp). 
1.2.3 Chronic Chagas Disease 
 Once the acute phase of Chagas disease has passed, patients enter into an 
asymptomatic stage termed indeterminate.  During the indeterminate phase of Chagas 
disease parasites are no longer found circulating in the blood but patients do have 
circulating antibodies to T. cruzi antigens and T. cruzi DNA can be detected by PCR 
assays (34).  Once patients begin to manifest symptoms of long term infection with T. 
cruzi they are considered to be in the chronic phase.  Approximately one third of patients 
with the indeterminate form progress to the chronic phase 10 to 30 years after the initial 
infection.  In the remainder of the patients the interaction between host immune system 
and innate parasite characteristics limits the tissue damage caused by the parasite and 
they remain in the asymptomatic indeterminate stage for life.  Given the subtle nature of 
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the acute infection and the asymptomatic indeterminate phase most patients who have 
Chagas disease are unaware. 
 Chronic Chagas disease affects a number of organ symptoms predominately the 
heart, followed by large intestine and esophagus.  There is a geographic pattern to which 
clinical forms are manifest with a dominance of megaesphagous and megacolon in the 
southern cone countries of South American countries whereas northern South America 
and Central America have relatively few cases of the megasyndromes (14).  This 
difference is thought to be due in part to the fact that isolates from humans infected in the 
southern cone countries tend to be of the lineage T. cruzi type II and those from northern 
South America and Central America from type I (35).   
 Chagas heart disease manifests as arrhythmias, congestive heart failure, and 
thromboembolism.  Early electrocardiographic changes in cardiac function include 
conduction abnormalities such as the classic finding of right bundle branch block, 
premature ventricular beats, and with more advanced changes atrial fibrillation, low QRS 
voltage and nonsustained ventricular tachycardia (36, 37).  Echocardiography may detect 
early wall motion abnormalities and advance disease is characterized by biventricular 
dilation and left ventricular aneurysm formation.  Right heart failure with its 
accompanying symptoms usually precedes the development of left heart failure.  Risk 
stratification based on clinical, electrocardiographic and echocardiographic data has been 
developed to predict death due to Chagas heart disease (38).  It has been shown that 
Chagasic patients with dilated cardiomyopathies have a much worse prognosis than 
patients with non-Chagasic cardiomyopathy (39).  However, treatment for Chagas heart 
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disease is similar to treatment for other causes of congestive heart failure with 
pacemakers showing benefit in the management of bradyarrhythmias (40).   
 Chronic Chagas disease affects the enteric nervous system and such destruction 
gives the classic megasyndromes of megaesophagus and megacolon.  Megacolonic 
patients present with progressive worsening constipation fecal impaction.  Rarely these 
patients may develop sigmoid volvulus or ischemic colitits.  Diagnostic studies such as 
barium enemas are effective in diagnosis of megacolon and almost all cases of Chagas 
megacolon show dilation and elongation of the sigmoid colon often with rectal 
involvement.  Proximal colonic dilation with Chagas is rare.  Conservative therapy 
consists of increasing fiber intake, judicious use of laxatives, and intermittent enemas.  
Manual disimpaction of obstructing fecalomas or surgical excision of affected bowel may 
be warranted in advanced cases (41). 
Megaesophagus presents similar to other forms of idiopathic achalasia with 
progressive difficulty swallowing food and regurgitation.  Some patients may persist with 
mild dysphagia for life while others may progress to achalasia with esophageal dilation.  
Barium esophogram will show a dilated esophagus with distal narrowing of the 
gastroesophageal junction representing the nonrelaxing lower esophageal sphincter (LES) 
with classic bird beak appearance.  Esophageal manometry demonstrates uncoordinated 
peristalsis and a nonrelaxing LES.  Treatment for achalasia is the same regardless of the 
etiology with modifications of food bolus to aid in esophageal transit.  
Esophagomyotomy via endoscopic balloon dilation is useful and the most severe cases 
may require esophagectomy (41). 
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1.3 Epidemiology 
 The WHO estimates that in 1985 when the first good epidemiological studies 
were done, that 25% of the inhabitants of South America, or 100 million people, were at 
risk for acquiring Chagas disease.  The prevalence of Chagas disease was approximately 
17.4 million cases with over 700,000 new cases per year (14).  Vector control programs 
such as the Southern Cone Initiative involving Argentina, Brazil, Chile, Paraguay, and 
Uruguay have shown to be effective.  Since 1982 these countries have seen a reduction in 
incidence ranging from 60% to 99% and it was estimated that in the year 2000 there were 
only 200,000 new cases worldwide (14).  Estimated current prevalence of Chagas disease 
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Figure 6. Estimated prevalence of Chagas disease in endemic countries and map of endemic zones in 




 Transmission of T. cruzi largely occurs through vectoral transmission as discussed 
above.  However, other important mechanisms of transmission include blood transfusion, 
congenital transmission, organ transplantation, oral transmission, and laboratory 
accidents.  Because of migrations of rural inhabitants of endemic zones to urban non 
endemic zones transmission by blood transfusion has also become a concern. In Lima, 
where over one third of Peru’s inhabitants live and is free from vectoral transmission, 
seroprevalence in 1993 among blood donors was 2.4% and in Santa Cruz, Bolivia it has 
been as high as 50% (14). Countries with no vectoral transmission of Chagas but a high 
number of migrants from infected countries are also at risk of transmitting the disease 
through blood donations especially since blood in these countries is not routinely 
screened for Chagas.  One study in Washington D.C. done among Salvadoran and 
Nicaraguan immigrants found a prevalence of 5% for Chagas disease (43).  Other studies 
done in blood donors have confirmed that infected migrants are living in the United 
States (44-47). It has been estimated that in the U.S. 90,000 and possibly up to 600,000 of 
the 12.8 million Latin American immigrants from 1981-2005 may be infected with T. 
cruzi (48). 
 Congenital transmission is an important mechanism of transmission in rural and 
urban centers.  Unpublished results from my experience in Santa Cruz, Bolivia showed a 
seroprevalence in 2007 of 25% among expecting mothers with only 1% transmission to 
the infant.  Other studies have shown congenital transmission rates between 1% and 7% 
(49, 50).  Transmission by organ transplantation, laboratory and hospital accidents have 
been reported, as well as outbreaks due to oral transmission following ingestion of food 
contaminated with triatomines or their excreta (51-53) . 
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Epidemiological surveys conducted in Peru have shown the highest prevalence to 
be in the southern departments of Arequipa, Ica, Moquegua, and Tacna.  Unpublished 
data obtained from the Chagas Control Program of the Regional Ministry of Health in 
Arequipa, Peru show 217 new cases of Chagas disease during 2000 through 2002 in all of 
Peru with 153 of those cases among the 3 southern departments of Arequipa, Tacna, and 
Moquegua.  Good epidemiological studies from Peru are lacking and the actual number 
of infected persons has been estimated to be around 680,000 with 6.7 million at risk for 
acquiring the infection (14).  Vector control has begun in the southern departments with 
surveillance programs in place with the hope to control vectoral spread and eliminate 
domestic transmission in these zones within the next few years (54).  The Andean 
countries of Bolivia, Peru, Colombia, and Venezuela hope to replicate the success of the 
Southern Cone Initiative in reducing Chagas disease transmission.  Significant progress 
has been made despite serious financial, political, and social hurdles with many more 
years of dedicated investment by these countries and international organizations 
necessary to achieve desired success. 
1.4 Diagnosis and Treatment 
 Acute Chagas disease is diagnosed by appropriate clinical history consistent with 
exposure and by detecting parasites in blood.  During the acute phase parasitemia motile 
parasites may be directly visualized by light microscopy in a drop of fresh blood.  To 
increase the sensitivity microhematocrit tubes may be used to visualize the parasite in the 
buffy coat or the Strout method to increase parasite concentration.  Indirect methods of 
parasite detection are xenodiagnosis with virgin Triatomines who are examined 1-2 
months after feeding on a patient’s blood for parasites in the hindgut.  Another method 
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involves culturing the patient’s blood in liver infusion tryptose (LIT) medium to check 
for parasite growth over the ensuing months.  Both indirect methods have been shown to 
be effective with highly variable sensitivity based on laboratory and patient 
characteristics.  The delay in diagnosis and difficulty in consistently conducting the 
indirect tests has decreased their use in routine diagnosis especially in resource poor 
countries.  PCR diagnosis of parasite DNA has shown promise as an effective diagnostic 
test for acute Chagas disease for over 10 years but lack of standardization and high costs 
has limited the adoption of this method for routine diagnosis (34, 55, 56). 
 The diagnosis of chronic Chagas disease relies on the detection of circulating IgG 
antibodies that bind to parasite antigens.  Currently there are more than 30 commercial 
kits available for the serological diagnosis of T. cruzi.  The three conventional 
immunologic tests in use are indirect hemagglutination (IHA), indirect 
immunofluorescence (IIF), and the enzyme-linked immunosorbent assay (ELISA).  
Because the antigens for these tests are usually derived from whole parasites, numerous 
cross reactions with leishmaniasis, malaria, syphilis, and other diseases can occur.  
Numerous tests have been developed using recombinant antigens to try and decrease 
cross reactivity (57-60).  The radioimmunoprecipitation assay (RIPA) uses radio-labeled 
T. cruzi antigens and tests the ability of patient serum to precipitate bands of 72kD and 
90kD on electrophoresis indicative of a positive reaction. The RIPA has shown to be 
highly sensitive and specific and has been used in the U.S. as a confirmatory test but due 
to its high cost and laborious procedure it has not been readily adopted by other countries 
(61, 62).  A positive result by any one of the three conventional tests should be confirmed 
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with a second conventional test, while a negative result needs no confirmation.  There is 
no definitive “gold standard” diagnostic assay for Chagas disease. 
An experimental assay to diagnose Chagas disease based on trypomastigote 
excreted-secreted antigens (TESA) has been developed (63).  T. cruzi trypomastigotes in 
culture spontaneously secrete antigens known as TESA which can then be isolated and 
used in an immunoblot assay for Chagas diagnosis.  Interestingly, sera from acute and 
chronic Chagas patients give two different banding patterns with immunoblot that allows 
distinction between the two.  The chronic patients have a characteristic broad band at 150 
to 160 kDa and acute Chagas patients show a ladder like pattern of 6 bands between 130 
and 200 kDa (Figure 7).  The TESA blot has successfully been used as a screening tool in 
Brazilian blood donors with inconclusive results from IIF and ELISA and was positive 
for 10 of 348 inconclusive sera with complete concordance with positive and negative 
controls(64) These results suggest that the TESA blot may be a more sensitive diagnostic 
tool that may aid in the diagnosis of Chagas disease.  The TESA antigens have also been 
adapted with success in ELISA assays for Chagas diagnosis with reported sensitivity of 





Figure 7. TESA blot showing the broad band at 150-160 kDa in chronic Chagas patients (P), and the 
ladder like pattern of 6 bands in acute Chagas patients (A), and Chagas negative (N) and control 
serum (C). 
 
Many studies have tested PCR as a diagnostic tool for chronic Chagas disease 
with sensitivities reported between 50% and 100% with the majority of studies showing a 
sensitivity of 90% (55, 56, 66, 67).  Because of the laboratory specifications, specialized 
personnel requirements, and expense, PCR is not likely to be useful as a large scale 
screening test but its value might lie in detecting cases of congenital transmission where 
parasitemia is no longer present, response to treatment, or confirming results when other 
diagnostic tests conflict (56, 68, 69). 
Treatment of persons infected with T. cruzi is largely ineffective and often 
inadequate.  Only two drugs have proven efficacy in the treatment of Chagas disease: 
nifurtimox (Lampit, Bayer 2502), and benznidazole (Rochagon, Roche 7-1051).   
Nifurtimox and benznidazole were introduced in 1967 and 1972 respectively and were 
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found to be effective for the treatment of acute Chagas infections with benznidazole 
being preferred due to its slightly less toxic side effect profile.  Nifurtimox is given orally 
in a dose of 8 to 10 mg/kg/day divided into four doses and continued for 90-120 days.  
The dose for children and adolescents is 25-20 mg/kg/day and 12.5-15 mg/kg/day 
respectively and therapy is continued for the same duration as in adults.  Benznidazole is 
also given orally in a dose of 5mg/kg/day divided into two doses for 60 days with the 
same dose regardless of age group.  In general, the younger the patient is the more 
tolerant they are of treatment and less likely they are to have serious side effects.  
Common side effects of both drugs include maculopapular rash that can progress to 
stevens-johnson syndrome, anorexia with significant weight loss, peripheral neuropathy, 
bone marrow suppression, diarrhea, and hepatotoxicity.  Side effects are the biggest 
reason why patients fail to finish treatment courses with most effects resolving with 
stopping the drug or lowering the dose.  Both drugs have demonstrated mutagenic 
potential in numerous studies but none involving humans (70). 
Treatment of chronic Chagas disease is controversial at best.  Some studies have 
shown that recent chronic Chagas disease in children, or infection occurring within the 
last 10 years, responds well to treatment with benznidazole with reported conversion to 
seronegative status among those treated at 58% and 62% while the placebo group was 0% 
and 5% (71, 72).  Cure was defined as conversion of serological test to negative at 3 and 
4 years follow up respectively.  It is recommended that all patients with recent, less than 
10 years, chronic Chagas disease be treated with appropriate pharmacotherapy especially 
all children under the age of 12.  In Peru the Chagas program will provide benznidazole 
free of charge to all Chagas patients 15 years of age or younger.  Despite evidence for 
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cure no long term study has been done to assess differences in clinical outcomes among 
these patients. 
Efficacy in the treatment of longstanding asymptomatic Chagas disease is less 
clear.  A systematic review found only 5 randomized control trials to assess the efficacy 
of treatment.  In all of the studies treatment of chronic Chagas patients resulted in 
decreased parasite load versus placebo as measured by xenodiagnosis, ELISA, or 
antibody titers after a few years of follow up(73).  However, no study has been done to 
correlate this decrease in evidence of parasites with long term clinical outcome.  A long 
term study with 6 to 18 year follow up showed that this negative serology, or “cure”, is as 
low as 8% in treated chronic Chagas patients (74).  Another randomized study 
demonstrated T. cruzi DNA detected via PCR in 100% of treated patients at 10 years 
follow up with no difference in EKG abnormalities in the treated and non treated groups 
(75).  A review of the literature found no role for treatment in chronic Chagas patients 
with cardiomyopathy (76).  A recent non-blinded, non-randomized trial found that 
chronic Chagas disease patients age 30-50 years old without heart failure treated with 
benznidazole for 30 days resulted in fewer patients with disease progression (4%) vesus 
(14%) in the control group as measured by a change to a more advanced Kuschnir group 
or death (77).  Despite the limitations of this study it may open the door to selective 
treatment of chronic Chagas patients. 
Given the common and severe side effects cause by treatment for those patients 
who are in the chronic phase of the disease, difficulty in assessing a cure, and no 
definitive study on the long term clinical benefit of treatment, the decision to treat this 
group of patients remains highly controversial.  It is also impossible at this time to 
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determine which set of chronic Chagas patients will remain asymptomatic their entire 
lives and which patients will have clinical manifestations regardless of treatment.  
Despite the controversy in treating patients with chronic Chagas disease, early diagnosis 
enables patients to receive the appropriate screening via EKG for early heart pathology 
and insertion of a pacemaker or automatic implantable cardioverter defibrillator (AICD).  
These interventions have been shown to benefit patients with arrhythmias. 
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2 Study Objectives 
 The purpose of this study was to evaluate the epidemiology of Trypanosoma cruzi 
infection, to identify risk factors for seropositivity, to evaluate the TESA blot, and to 
characterize cardiac findings of patients with Chagas disease in a rural setting near 
Arequipa, Peru.  No systematic studies have been performed in this area and reliable data 
about prevalence and risk factors will help determine Chagas disease burden, and help 
guide vector control strategies.  Additional information about the effectiveness of the 
TESA blot in a community screening will shed light on its value in the diagnostic 
armamentarium for Chagas disease.  
 
Specific objectives of this study were the following: 
1. What is the prevalence of seropositivity to T. cruzi in a population living in rural 
Chagas-endemic communities near Arequipa, Peru? 
2. How does the TESA blot compare to traditional Chagas diagnostic methods? 
 
This work will aid Peru and the Andean countries as they continue their campaign to 
eradicate vector transmission of Chagas disease by contributing valuable up to date 
information on prevalence and risk factors for contraction of Chagas disease in a rural 
environment.  The clinical information provided in this study can shed light on regional, 
differences in cardiac pathology.  The study is in alignment with the WHO’s Millennium 
Development goals of combating disease in developing countries that contributes to 
morbidity and mortality.  
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3 Methods 
3.1 Study Population and Sites 
 The study site is the town of Quequeña, Peru, elevation of 2300 m (7,545 ft), 
located about 25 km south of Arequipa.  The village has a population of 774 with 236 
under the age of 18 according to the 2005 census conducted by Peru.  It is a rural, 
agricultural town that is isolated from the city of Arequipa, population 850,000, by 
distance and geography.  There is no continuity of the sprawling slums of Arequipa with 
the town of Quequeña.  Its economic survival is based almost exclusively upon 
agriculture and animal husbandry.  In the community there is a school for primary 
education and students must travel to Arequipa for secondary education.  A local health 
post is open 5 days a week in the mornings staffed by a nurse and two assistants.  Minor 
check ups, vaccinations, and some medications are available at the health post.  A nurse 
midwife and general physician attend at the clinic one day a week.  No acute, overnight, 
or obstetrical care is available.  Quequeña as well as other rural towns have suffered 
population declines in recent decades as many rural inhabitants have migrated to the 
cities because of terrorism or economic opportunities.  Very few immigrants live in 
Quequeña so the majority of infected persons probably contracted Chagas in Quequeña.  
See appendix 2 for satellite images of the study site. 
The majority of homes are of poor construction and many date to the first half of 
the 20th century.  The community infrastructure consists of electricity and plumbing that 
brings water from local tanks into most homes but no sewer system exists.  The water 
was unchlorinated during the duration of this study.  Many homes also raise guinea pigs, 
rabbits, dogs, chickens, sheep, and cattle in close proximity to their dwellings which 
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supply an ideal habitat and blood meals for T. infestans while providing an important 
reservoir for T. cruzi infection.  Community members recognize T. infestans by the local 
name of “chirimacha” and are often aware of the infestation but knowledge of T. cruzi 
infection by T. infestans was limited.  T. infestans excreta could be found on the walls 
and bedding of homes prior to fumigation campaigns. 
 In the community of Quequeña an extensive entomologic and ecologic survey 
was conducted in December of 2006 by Michael Levy.  Entomological collection was 
carried out in coordination with the Arequipa Regional Ministry of Health Vector Control 
Program’s insecticide spraying campaign.  Entomological surveillance included timed 
collection of T. infestans (30 minutes by two collectors for a total of one person-hour) in 
houses and peridomestic animal corrals after application of deltamethrin (K-Othrine) 
insecticide by the Ministry of Health vector control team.  296 houses were GPS-mapped 
in Quequeña.  The T. infestans collected were analyzed for the presence of T. cruzi in the 
hindgut. 
  
3.2 Community Based Survey 
 All community based work was done in coordination and with the support of the 
Ministry of Health and the regional Chagas Disease Control Program directed by Dr. 
Juan Cornejo.  Local support was obtained by working closely with the local health post, 
government and religious leaders.  Numerous community meetings were conducted to 
notify the community of the objectives and design of the study.  A meeting was held at 
the local primary school with parents and teachers to detail the inclusion of children in 
the study as most cases of Chagas disease are contracted during childhood.  In addition to 
explaining the purpose of the study at each meeting, a presentation designed by the 
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Chagas Control Program was given to educate the community about Chagas 
transmission, detection, and prevention. 
 After community education programs were completed, a house to house census of 
the town was done with 284 inhabited houses and 602 residents surveyed.  Two 
weekends were programmed for community wide serosurveys where residents came to 
the health post or church and after informed consent 5cc of blood was obtained.  After 
parental consent was obtained one day was spent in the primary school conducting the 
serosurvey with parents present.  As outlined in the consent form, participation was 
voluntary and any resident who declined to participate could contact the Ministry of 
Health hospital for evaluation of Chagas disease.  In order to facilitate community 
participation, individuals who were unable to come to the scheduled serosurveys were 
visited in their homes up to 4 times by study nurses early in the morning or evening. 
3.3 Case Control Study 
 All seropositive community residents and two age and sex matched community 
controls were invited to participate in a nested case-control study to evaluate risk factors 
for Chagas and EKG differences.  All participants were administered a questionnaire and 
a 12 lead EKG was done with a portable EKG machine at the local health post.  The 
EKG’s were read by a local cardiologist who was privy only to patient age and their 
unique laboratory code.  
3.4 Epidemiologic Data Collection and Analysis 
 Data collected by Michael Levy and team in December of 2006 includes T. 
infestans field data, and GPS location of all houses.  Census information, serosurvey, 
laboratory analysis, and case-control study was performed by myself.  All questionnaires 
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were translated by a certified Spanish translator and administered by a local nurse fluent 
in the language.  Data analysis was done using SPSS statistical software. 
3.5 Specimen Collection and Laboratory Testing 
 All blood specimen collection was done using new material donated by the 
Centers for Disease Control and Prevention (CDC) of the United States.  Only study 
nurses drew samples and they followed universal precautions and standard sterile 
technique.  Blood was obtained using Vacutainer blood collection needles, 21 G x 1.25 
inches and 5 mL Vacutainer red top plastic serum tubes from BD (#368607, #367814).  
Samples were kept on ice, stored at -4°C overnight, and processed the next morning into 
aliquots of serum and clot that were then stored at -20°C.  One aliquot of specimens were 
given to the Ministry of Health’s diagnostic laboratory for quality control and the other 
was sent overnight to the laboratory of Dr. Robert Gilman at the Universidad Cayetano 
Heredia in Lima, Peru for laboratory testing. 
 All samples were screened by commercial ELISA kit Chagatek following the 
manufacturer’s instructions (bioMérieux: distributed by Quimica Suiza, Lima, Peru).  All 
positives were confirmed with indirect immunofluorescence (IIF) as well as a group of 
negatives.  Specimens were considered positive when fluorescence was observed with a 
dilution of 1:16 or higher.  The TESA blot was performed as described previously (63) on 
all positive samples and a subset of negative samples. 
3.6 Treatment of Seropositive Children 
 In accordance with the guidelines of the Peruvian Ministry of Health all 
seropositive children under 15 years of age would be treated with benznidazole for 60 
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days (10 mg/kg/d for children less than 10 years old; 5-7 mg/kg for children 10-15 years 
old per Roche Brazil) (78).  No children in this age group were seropositive. 
3.7 Informed Consent and Confidentiality 
 Appendix 1 shows the consent forms in English that were used for this study.  
Consent forms were translated into Spanish by a certified translator and consent forms 
were read and explained by study nurses fluent in Spanish.  Consent was obtained by 
signature or fingerprint.  Each individual was assigned a unique laboratory code that was 
affixed to all laboratory samples.  Names of participants were entered into the census 
database along with their unique code to provide a key.  All other databases used the code 
numbers only.  All databases are only available to study investigators and computers are 
secured with passwords.  Hard copies of questionnaires are locked in a file cabinet in 
Lima, Peru. 
3.8 IRB Approval 
 The amendment for this study was approved by the Johns Hopkins Bloomberg 
School of Public Health Institutional Review Board on April 10, 2007 (IRB# 
H22.05.01.26.A1).  Approval was also obtained from the IRB of A.B. PRISMA on April 
3, 2007 (IRB# CE152.07) in Lima, Peru. 
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4 Results 
 Of the 602 people surveyed to be living in Quequeña, blood samples were taken 
from 445 (73.9%) with 237 female and 208 male.  Table 1 shows the gender breakdown 
by decade for participants in the study.  
 
Table 1.  Age and sex of participants. 
Age (years) Sex 
  F M Total 
<10 31 33 64 
10 - 19 52 45 97 
20 - 29 39 30 69 
30 - 39 38 30 68 
40 - 49 29 30 59 
50 - 59 21 8 29 
60 - 69 12 15 27 
70 - 79 11 12 23 
80+ 4 5 9 
Total 237 208 445  
Mean        31.93 years 
Median          29 years 
Range      2 - 83 years 
 
Of the 284 households in Quequeña, 242 (85.2%) were sprayed, and fifty-eight 
(24.0%) were infested with triatomines.  Nineteen households (7.85%) harbored 
triatomines infected with T. cruzi.  This signifies that 41.1% of participants in the study 
lived in a household where the insect vector was present, and 11.9% lived in a household 
with T. cruzi infected triatomines, see table 4.  3 households refused to participate in the 
spraying campaign, 28 households were abandoned or closed, 2 were vacant lots, and 9 
households were public spaces that were sprayed but not surveyed.  95% of participants 
in the study gave basic information regarding their housing status, i.e. electricity, potable 
water, sewer, and material of floor.  These housing characteristics are shown in relation 




Table 2. Housing characteristics and T. infestans status 
T. infestans status 
Positive Negative Total 





Yes 162 38.2% 220 51.9% 382 90.1%
No 18 4.2% 24 5.7% 42 9.9%
Electricity 
Total 180 42.5% 244 57.5% 424 100.0%
Yes 170 40.1% 209 49.3% 379 89.4%
No 10 2.4% 35 8.3% 45 10.6%
Potable 
water 
Total 180 42.5% 244 57.5% 424 100.0%
Yes 0 .0% 79 19.1% 79 19.1%
No 175 42.3% 160 38.6% 335 80.9%
Sewer 
Total 175 42.3% 239 57.7% 414 100.0%
Cement 39 9.2% 85 20.1% 124 29.3%
Dirt 138 32.6% 153 36.2% 291 68.8%
Other 3 .7% 5 1.2% 8 1.9%
Material 
of Floor 
Total 180 42.6% 243 57.4% 423 100.0%
 
 
Table 3. Housing characteristics and T. cruzi status 
 T. cruzi status 









Electricity Yes 50 27.8% 112 62.2% 162 90.0%
  No 0 .0% 18 10.0% 18 10.0%
  Total 50 27.8% 130 72.2% 180 100.0%
Potable 
water Yes 46 25.6% 124 68.9% 170 94.4%
  No 4 2.2% 6 3.3% 10 5.6%
  Total 50 27.8% 130 72.2% 180 100.0%
Sewer Yes 0 .0% 0 .0% 0 .0%
  No 50 28.6% 125 71.4% 175 100.0%
  Total 50 28.6% 125 71.4% 175 100.0%
Material of 
Floor Cement 18 10.0% 21 11.7% 39 21.7%
  Dirt 29 16.1% 109 60.6% 138 76.7%
  Other 3 1.7% 0 .0% 3 1.7%
  Total 50 27.8% 130 72.2% 180 100.0%
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Table 4.  Presence of insect vector and T. cruzi compare with age and sex. 
 T. infestans status T. cruzi positive T. infestans 
  Negative Positive Negative Positive 
  N N % N N % N N % N  N %
Sex F 145 32.6% 92 20.7% 214 48.1% 23 5.2%
  M 117 26.3% 91 20.4% 178 40.0% 30 6.7%
  Total 262 58.9% 183 41.1% 392 88.1% 53 11.9%
Current Age 
q 10 years 
(Banded) 
<10 
39 8.8% 25 5.6% 56 12.6% 8 1.8%
  10 - 19 54 12.1% 43 9.7% 84 18.9% 13 2.9%
  20 - 29 35 7.9% 34 7.6% 58 13.0% 11 2.5%
  30 - 39 45 10.1% 23 5.2% 60 13.5% 8 1.8%
  40 - 49 35 7.9% 24 5.4% 55 12.4% 4 .9%
  50 - 59 22 4.9% 7 1.6% 28 6.3% 1 .2%
  60 - 69 14 3.1% 13 2.9% 24 5.4% 3 .7%
  70 - 79 15 3.4% 8 1.8% 20 4.5% 3 .7%
  80+ 3 .7% 6 1.3% 7 1.6% 2 .4%
  Total 262 58.9% 183 41.1% 392 88.1% 53 11.9%
 
Figure 8 shows each household as a circle with its spatial distribution determined 
by a global position system (GPS).  Three figures display the location of households with 
T. infestans, vectors positive for T. cruzi, or households with Chagas positive inhabitants.  
Of the 15 patients positive for Chagas disease, 9 lived in a house positive for triatomines 
(60%), of which 3 were positive for T. cruzi (33%).  2 of those 3 patients who inhabited a 
T. cruzi positive household shared the same house.  Rough clustering of the insect vector, 
T. cruzi households, and Chagas patients exists as seen by the figure below. 
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(a) T. infestans positive households 
 
(b) T. cruzi positive households 
 
(c) Chagas positive inhabitants 
 
Figure 8. GPS location of households in Quequeña, each circle represents a household. Blue circles 
represent triatomine positive households (a), teal circles represent households with T. cruzi infected 
triatomines (b), and red circles represent households with T. cruzi positive inhabitants (c). 
 
15 (3.37%) patients were positive for Chagas disease by ELISA and confirmed by 
immunofluorescence, see Figure 9 for ELISA results with OD cutoff values.  The TESA 
blot was also performed on all positives and a random subset of negative blood samples.  
In this community based survey the TESA blot had a sensitivity of 93% and a specificity 
of 100%, see Table 5.  All negative results of the TESA blot matched with the ELISA 
and IIF results.  All 14 positives by TESA were also positive by ELISA, with one ELISA 


















































































Figure 9. ELISA results and OD cutoff values.  15 total samples were above the cutoff value. 
 
Table 5. Sensitivity and specificity of the TESA blot and immunofluorescence (IIF). 
Assay Positive Negative Total Sensitivity Specificity PPV NPV 
ELISA 15 430 445     
IIF 15 19 34 100% 100% 100% 100% 
TESA-
Blot 
14 20 34 93% 100% 100% 83% 
 
 Serostatus for Chagas disease compared with age and sex variables is shown in 
Table 6 and Figure 10 displays percent seropositive by decade of life. 
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Table 6.  Serostatus compared with sex and age by decade. 
 ELISA result 
  Negative Positive Total 
  N  N % N  N % N  N %
Sex F 228 51.2% 9 2.0% 237 53.3%
  M 202 45.4% 6 1.3% 208 46.7%
  Total 430 96.6% 15 3.4% 445 100.0%
Current 
Age 
<10 64 14.4% 0 .0% 64 14.4%
  10 - 19 97 21.8% 0 .0% 97 21.8%
  20 - 29 64 14.4% 5 1.1% 69 15.5%
  30 - 39 64 14.4% 4 .9% 68 15.3%
  40 - 49 55 12.4% 4 .9% 59 13.3%
  50 - 59 29 6.5% 0 .0% 29 6.5%
  60 - 69 27 6.1% 0 .0% 27 6.1%
  70 - 79 22 4.9% 1 .2% 23 5.2%
  80+ 8 1.8% 1 .2% 9 2.0%
  Total 430 96.6% 15 3.4% 445 100.0%




















                                                            Age (years) 
Figure 10. Percent seropositive for Chagas disease by age. 
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Electrocardiograms (EKGs) were performed on 37 people, 9 of whom were 
positive for Chagas disease and the other 28 were age and sex matched controls.  All 
EKGs of Chagas positive patients were normal and 27 of 28 EKGs were normal in the 
control group, see Table 7.  The lone abnormal EKG belongs to a 74 year old Chagas 




My study was a successful serosurvey for Chagas disease in a rural village of Peru in 
coordination with the regional Ministry of Health Chagas Control Program insecticide 
campaign.  The local government has allocated sufficient funds to begin insecticide 
campaigns in many regions surrounding Arequipa, Peru but lacks the resources to 
conduct detailed epidemiological surveys or laboratory analysis of the inhabitants.  It was 
important to conduct the serosurvey in coordination with the insecticide campaign to 
ensure that the vector transmission cycle was broken before determining the burden of 
disease.  All data from my project was shared with Dr. Juan Cornejo, Director of the 
Chagas Control Program in Arequipa, Peru. 
I found that the prevalence of Chagas disease in this rural village to be 3.4% of those 
sampled.  This is consistent with previous estimates in other rural sites in Arequipa 
(personal communication with Cornejo, J.).  Of note was an absence of infected persons 
in the age range of 2-20 years old and 50-70 years old.  This is especially unusual 
because children in Quequeña recall being bitten by the insect vector and there is ample 
evidence of recent triatomine excreta on the walls and bedding of children indicating 
contact between the vector and children.  42% of children lived in houses where the 
insect vector was present and 13% where the vector was positive for T. cruzi.  There have 
been no previous insecticide campaigns and speaking with people from the village only 
one family had independently fumigated their house.  No major events occurred twenty 
years ago that would explain the negative findings in children.   
Other rural studies in Brazil have shown an increase in prevalence beginning at birth, 
peaking around 20 years of age with a gradual decline due to excess mortality in middle 
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age (79).  In rural Guatemala the same pattern was seen with the peak about 30 years of 
age (80).  A recent study conducted in a peri-urban zone among children of Arequipa 
found a prevalence rate of 5.3% with clusters of infected children loosely clustered 
around T. cruzi positive vector infested homes (81).  They also demonstrated that a 
child’s risk of being seropositive increased by 20% per year of age and by 4% per vector 
found inside the home. 
One possibility that would reduce the exposure time of teenagers is the lack of 
secondary education in the village of Quequeña, meaning all students must travel to 
Arequipa to complete their studies.  Many live in Arequipa during the school week and 
spend the weekends at home with family.  This would reduce their exposure to the vector 
but only during their teenage years and does not explain fully the lack of seropositive 
children.  
Given the rustic nature of the housing in Quequeña it was not surprising to find that 
24% of households harbored the insect vector and 7.85% were positive for T. cruzi.  
There exists a correlation between being infested with triatomines and basic 
measurements of household services.  38.2% of households positive for triatomines had 
electricity while 52.9% of households negative for triatomines had electricity.  This was 
also true of potable water (40.1% vs. 49.3%), and sewer (0.0% vs. 19.1%).  There was no 
correlation between type of floor.  This same correlation held true for presence of T. cruzi 
and electricity (27.8% vs. 62.2%), and potable water (25.6% and 68.9%).  Clusters of 
vector infested and T. cruzi positive homes were in the “older” part of town and can be 
seen on the GPS maps.  This part of town contains homes that are in a more dilapidated 
state with an environment more suitable to triatomines. 
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There is a risk for reinfestation with T. infestans and this has been documented to 
occur in other rural sites.  However, because of the isolated nature of Quequeña 
reinfestation is likely to occur much slower than in a peri-urban community.  The 
community has established a vigilance campaign to have community members notify the 
health post if they find evidence of reinfestation.  A study from Argentina found 
reinfestation of a rural community two years after spraying from a pig pen that was 
missed in the initial campaign(82).  The vector was found in households 450 meters 
surrounding the putative site.  T. infestans has been shown to be able to spread via 
walking up to 42 meters and spread beyond is thought to occur to occasional flight(83).  
If there was a reinfestation site like this in Quequeña it would put the majority of the 
community at risk depending on its location.  However, a study in the Bolivian highlands 
(2,750 m asl) showed no evidence of genetic spread among isolated triatomine 
populations suggesting that at this altitude walking is the only method of dispersion(84). 
I also showed that no patients with Chagas disease had any evidence of EKG 
abnormalities.  EKG abnormalities, classically right bundle branch block, can be used to 
screen for disease progression and future arrhythmia treatment.  Because only one third 
of Chagas patients go on to develop clinical disease my lack of positive cases makes it 
probable that it was due to pure chance.  This lack of clinical presentation may also be 
due to a less virulent strain of the parasite or the host immune response in the community 
(85). 
The diagnosis of Chagas disease was done according to established criteria as all 
positives were confirmed by a different assay.  In my study all serum samples were 
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screened by ELISA and confirmed by indirect immunofluorescence (IIF).  There was 
complete concordance between the two tests.   
I was also the first person to test the TESA blot in a community setting.  Previously 
it has been validated as a sensitive and specific test in serum banks but has never been 
employed in a community based setting (63, 64).  In this study the TESA blot had a 
sensitivity of 93% and a specificity of 100% proving that it can be successfully employed 
in community surveys.  The advantage of the TESA blot is that is can distinguish 
between an acute and chronic infection which enables the clinician to begin treatment 
without reservation in the acute patients.  Results are available in a few hours with pre-
made immunoblot strips.  No expensive microscope or ELISA reader is required for 
diagnosis and it does not cross react with leishmaniasis(63, 64). 
The disadvantage to the TESA blot is that it is unavailable commercially although 
similar systems exist.  In order to produce the assay a laboratory must have active T. cruzi 
cultures and the ability/equipment to perform western blots.  If this infrastructure exists it 
would be much cheaper to produce locally than to purchase commercial systems.  Once 
the immunoblots are made they can be used with relatively few reagents in a more 
isolated environment.  My experience is that reading of the strips is more qualitative than 
quantitative and can often lead to a questionable result that requires repeat or alternative 
testing. 
In summary, my study was able to gather important clinical information from a rural 
site endemic for Chagas disease.  This clinical information will help the local Chagas 
Control Program as it continues its vector control campaign by allowing them to more 
accurately predict disease burden in such settings.  I was able to successfully employ the 
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TESA blot as a diagnostic test in a community based setting which will allow its 
expanded use as a Chagas diagnostic assay. 
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6 Appendix 1 
6.1 Consent Form for Chagas’ Serosurveys 
Fleisch-Kincaid Reading Level: 7.9 (in MS Word) 
 
Please ask our study staff to explain any words or information you do not understand. If you 
agree to be in the study, we will give you a copy of this consent form. 
 
Introduction   
Asociación Beneficia PRISMA, the Regional Office of the Peruvian Ministry of Health in 
Arequipa, Johns Hopkins University, USA, and the Centers for Disease Control and Prevention, 
USA, are doing a research study in Perú to learn more about an illness called Chagas’ disease.  
This illness causes fevers, swelling in the face or eyes, weight loss and weakness. Many years 
later, it can cause heart disease, difficulty swallowing, and death. Chagas’ disease is caused by a 
parasite carried by the chirimacha, a large insect.  We are asking you/your child to take part in 
this study because there are chirimachas and people with Chagas’ disease living in your district.  
 
Purpose 
We wish to learn more about why some people get Chagas’ disease and others do not.  This 
information will help to plan ways to stop the spread of Chagas’ disease in the future.  
 
Blood test. 
For the above purpose, we will take about 1 teaspoon (about half a teaspoon for children under 5) 
of blood from your/your child’s arm.  We will do blood tests for Chagas’ disease.  We will give 
you the results of the Chagas’ tests after 1 month.    
 
Follow-up if Chagas’ blood test is positive.   
If the first Chagas’ blood test is positive, we will perform a second test on the same blood that we 
collected to make sure that the result is right.  The first test is very sensitive.  That means it can 
sometimes be positive in people without Chagas’ disease.  The second test is stricter.  If both 
blood tests are positive, we will give you a letter to go to the Ministry of Health clinic for 
treatment.   
If both blood tests are positive:  
1. We will visit you to give you the results and ask you to be another study. We will also ask 
some people with negative results to be in this second study.  It is up to you whether you/your 
child will be in this study. . 
2. For children younger than 15 years old with positive blood tests, we will write a letter for you 
to take your child to the nearest health post or district hospital to get adequate treatment. The drug 
to treat Chagas’ disease is given for free by the Ministry of Health.  For people older than 15 
years old who are positive for infection, we will refer you to a doctor for a check-up to see if you 
have damage to your heart from Chagas disease.  If necessary, we will help with the costs of 
transportation. 
3. The treatment with antiparasitic medicine is not given to people older than 15 years.   
 
Benefits.   
1. This study will help your child to get antiparasitic treatment free of cost if we find your child 
has Chagas’ disease. The treatment will be given by doctors under the supervision of the Ministry 
of Health.  If the Ministry does not have medicine available, the project will buy the medicine 
(Nifurtimox or Benznidazole) so that the Ministry doctors can treat your child.   For people older 
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than 15 years old who are positive for infection, we will refer you to a doctor for a check-up to 
see if you have damage to your heart from Chagas disease. 
2.  The results of the study will help us plan better programs to find, treat, and prevent Chagas’ 
disease for your community and other communities in Perú. 
 
Risks and discomfort.  
You/your child will feel a small sting like a pin prick when we take the blood sample. You/your 
child may get a small bruise where the needle goes in but this will go away soon.  Rarely taking 
blood may cause infection, but we will try to prevent this by using sterile needles and cleaning the 
skin before taking the blood sample. 
 
Alternatives to this study.  
You/your child can be tested for Chagas disease at the district hospital. 
 
Being in the study is voluntary.   
It is up to you whether you/your child will be in the study.  You/your child may decide not to take 
part, or to quit the study at any time.  This would not affect your/your child’s care or any other 
benefits.  
 
Compensation.   
If you are hurt as a result of being in this study, the study staff will help you to receive treatment 
at the closest District Hospital. This treatment will be free of charge.  Johns Hopkins University, 
the CDC, and A.B. PRISMA do not normally pay for harm done to you as a result of being in a 
research study.  However, by signing this consent form and agreeing to be in this study, you are 
not giving up any of your rights.   
 
Confidentiality.   
Your name/your child’s name will be kept private to the extent allowed by law. We will record 
your name and address on a list, so that we can tell you the test results. The forms that record 
study information will have a code number, which will be linked to your/your child’s name. Only 
the health workers doing our study will have access to the list of names. The list will be destroyed 
once the study is done. 
 
Questions.  
If you have questions about the study, please call Dr. Juan Cornejo, Chagas’ Disease Program, 
Arequipa Region, Ministry of Health (54 28 1536) or Dr. Robert Gilman (01 464-0221). 
 
Human subjects contact.  If you have questions about your rights as a research subject, or if you 
believe you have been harmed by being in the study, please contact the head of the ethics 
committee of one of the 2 local institutions working on the project: Dr. Ricardo López Ingunza, 
President of the Ethics Committee of the Instituto Nacional de Salud (telephone: 01-4719920, 
extension 175); and/or Dr. Salomón Zavala, President of the Ethics Committee of A.B. PRISMA 
(telephone 464-0490, extension 246). Both committees will be responsible to ensure your rights 
as a participant. 
 
Name of participant (print) 
 ________________________________________________ 
 
I have read this consent form or someone explained it to me. I freely agree to be in/(to have my 
child be in) the study. 
 
 42
____________________________    ___/___/___ 
Signature or fingerprint of participant    Date 
Required for participants > 18 
 
________________________________    ___/___/___ 
Signature or fingerprint of parent/guardian   Date 
Required for participants < 18  
 
 
________________________________    ___/___/___ 
Signature of witness          Date 
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STORAGE OF BLOOD SAMPLES 
 
If you agree, we will store the sample after the study is over (in about 2 years).  We will use the 
sample to try out future tests for Chagas’ disease or other diseases to see if they work. We may 
also perform studies on the DNA in the blood clot.  After our study ends, we will take your code 
number off the sample when we store it. After that there will be no way to connect you to the 
blood sample. This means we will not be able to report the results of future tests to you.  We may 
also look in your sample for blood factors that make people more likely to get sick with Chagas’ 
disease, but we will only do this after we take your code number off the sample. We will not do 
HIV testing on the sample.  If you are willing to have us test your sample now, but you do not 
want us to store the sample, you can still take part in the study.  We will record your wishes about 
whether we can store you/your child’s sample on this form.  
 
I give permission to store my/my child’s blood sample. 
 
________________________________    ___/___/___ 
Signature or fingerprint of participant    Date 
 
________________________________    ___/___/___ 
Signature of witness          Date 
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6.2 Consent Form for Chagas’ Case-Control Studies 
Fleisch-Kincaid Reading Level: 8.0 (in MS Word) 
 
Please ask our study staff to explain any words or information you do not understand. If you 
agree to be in the study, we will give you a copy of this consent form. 
 
Introduction   
Asociación Beneficia PRISMA, the Regional Office of the Peruvian Ministry of Health in 
Arequipa, Johns Hopkins University, USA, and the Centers for Disease Control and Prevention, 
USA, are doing a research study in Perú to learn more about an illness called Chagas’ disease.  
This illness causes fevers, swelling in the face or eyes, weight loss and weakness. Many years 
later, it can cause heart disease, difficulty swallowing, and death.  Chagas’ disease is caused by a 
parasite carried by the chirimacha, a large insect.  We are asking you/your child to take part in 
this study because there are chirimachas and people with Chagas’ disease living in your district.  
 
Purposes 
1.  We wish to learn more about why some people get Chagas’ disease and others do not.  This 
information will help to plan ways to stop the spread of Chagas’ disease in the future.  
2.  We would like to learn how the disease affects the heart . We hope this information will help 
people to get better treatment in the future. 
 
What we will ask you to do as part of this study 
We are asking two groups of people to be in this study. First, we are asking all people whose 
blood test was positive for Chagas’ disease. Second, we are asking some people with negative 
blood tests to take part in order to compare their results to those of people with a positive.test. If 
you agree, we will do the following: 
1.  We will ask you some questions about you and the members of your household, their health 
and past illnesses, and about your house, land, and animals.  All of this will take from 30 minutes 
to one hour. You do not have to answer any questions you do not want to. 
2. We will collect insects from inside and outside your house, and from your animals’ housing. 
We will use a small machine like a radio to show the exact location of your house on a map. If we 
already did these things in the past, we ask your permission to use this information in this study. 
3.  We will arrange for you/your child to have a test called an electrocardiogram (EKG), at the 
local health post. For this test, the nurse will place several sticky pads on you/your child’s chest, 
arms, and legs that are attached to wires to an EKG machine.  This machine measures the 
electrical signals in the heart and can show certain problems of heart function.  This will take 
about ten minutes. 
4. We will arrange for you/your child to have a test called an echocardiogram, at the hospital in 
Arequipa. For this test, the doctor will use a small microphone to see your heart. This works like 
radar and does not hurt. It allows the doctor see the size and shape of your heart and how well it is 
working.  This will take about 30 minutes.  We will arrange for transportation to and from the 
hospital. 
 
Benefits.   
1. This study will help your child to get antiparasitic treatment free of cost if we find your child 
has Chagas’ disease.  The treatment will be given by doctors under the supervision of the 
Ministry of Health.  If the Ministry does not have medicine available, the project will buy the 
medicine (Nifurtimox or Benznidazole) so that the Ministry doctors can treat your child. 
2.  For adults with infection, we will help you to be examined by a heart doctor who will 
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recommend whether you need any treatment. 
3. The results of the study will help us plan better programs to find, treat, and prevent Chagas’ 
disease for your community and other communities in Perú. 
 
Risks and discomfort.  
The heart tests may cause some minor inconvenience or discomfort, but will not be painful. They 
will not cause you any harm. 
 
Alternatives to this study.  
You may go to the district hospital for health care if you believe you have Chagas disease. Perú 
has national guidelines for treatment of Chagas’ disease.  The study will not change the treatment 
if you/your child is infected with Chagas’ disease. 
 
Being in the study is voluntary.   
It is up to you whether you/your child will be in the study.  You/your child may decide not to take 
part, or to quit the study at any time.  This would not affect your/your child’s care or any other 
benefits.  
 
Compensation.   
If you are hurt as a result of being in this study, the study staff will help you to receive treatment 
at the closest District Hospital. This treatment will be free of charge.  Johns Hopkins University, 
the CDC, and A.B. PRISMA do not normally pay for harm done to you as a result of being in a 
research study.  However, by signing this consent form and agreeing to be in this study, you are 
not giving up any of your rights.   
 
Confidentiality.   
Your name/your child’s name will be kept private to the extent allowed by law. We will record 
your name and address on a list, so that we can tell you the test results. The forms that record 
study information will have a code number, which will be linked to your/your child’s 
name. Only the health workers doing our study will have access to the list of names. The list 
will be destroyed once the study is done. 
 
Questions.  
If you have questions about the study, please call Dr. Juan Cornejo, Chagas’ Disease Program, 
Arequipa Region, Ministry of Health (54 28 1536) or Dr. Robert Gilman (01 464-0221). 
 
Human subjects contact.  If you have questions about your rights as a research subject, or if you 
believe you have been harmed by being in the study,please contact the head of the ethics 
committee of one of the 2 local institutions working on the project: Dr. Ricardo López Ingunza, 
President of the Ethics Committee of the Instituto Nacional de Salud (telephone: 01-4719920, 
extension 175); and/or Dr. Salomón Zavala, President of the Ethics Committee of A.B. PRISMA 
(telephone 464-0490, extension 246). Both committees will be responsible to ensure your rights 
as a participant.  
 
Name of participant (print) 
 ________________________________________________ 
 
I have read this consent form or someone explained it to me. I freely agree to be in/(to have my 
child be in) the study. 
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____________________________    ___/___/___ 
Signature or fingerprint of participant    Date 
Required for participants > 18 
 
________________________________    ___/___/___ 
Signature or fingerprint of parent/guardian   Date 
Required for participants < 18  
 
________________________________    ___/___/___ 
Signature of witness          Date 
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6.3 Survey Assent Form for Children 7-15 Years Old   
Fleisch-Kincaid Reading Level: 5.3 (MS Word) 
 
We would like to learn more about an illness called Chagas’ disease.  It causes fevers, swelling in 
the face or eyes, weight loss, heart problems, difficulty swallowing and weakness.  Also this 
study will help us plan better programs to find, treat and prevent the illness. 
 
If you agree, we will do a blood test.  We will take one teaspoon of blood from your arm to do a 
test for Chagas’ disease.  This means you will feel a small stick.  If this test is positive, we will 
make sure you are not sick and we will send you to the doctor for medicine.  
 
If the Chagas’ disease blood tests are positive, we will send you to the doctor for evaluation and 
treatment with medicines.  The purpose of these medicines is to get rid of the Chagas’ infection. 
 
Your parents have said it is all right for you to be in the study. You do not have to join this study 
if you do not want to. If you do not, it will not affect anything at home or in your health care.  
You can quit the study at any time.  If you do decide to join, you will help us to help the people in 
this town protect themselves against Chagas’ disease. 
 
We will record your name and address, so that we can tell your parents/guardians the results of 
our tests. We will not give the results of your tests to anyone but you, your parent/guardian and 




Name of participant (print) 
 ________________________________________________ 
 




____________________________    ___/___/___ 




________________________________    ___/___/___ 
Signature of witness          Date 
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6.4 Case-Control Assent Form for Children 7-15 Years Old   
Fleisch-Kincaid Reading Level: 5.3 (MS Word) 
 
We would like to learn more about an illness called Chagas’ disease.  It causes fevers, swelling in 
the face or eyes, weight loss, heart problems, difficulty swallowing and weakness.  Also this 
study will help us plan better programs to find, treat and prevent the illness. 
 
We will ask all children with a positive Chagas test to take part in this study. We will also ask 
some children with negative Chagas tests to take part. This is so we can compare the results of the 
children with positive tests to the results of the children with negative tests. This helps us 
understand why some children get Chagas and others do not. 
 
If you agree, we will do two tests to check how your heart works. The first test is the 
electrocardiogram. For this test, we will put small sticky pads on your chest to see how your heart 
is beating. The second test is the echocardiogram. For this test we will use a small microphone on 
your chest so the doctor can see how your heart looks. These tests will not hurt. We will also ask 
some questions about your health, where you sleep, and what animals your family has. 
 
Your parents have said it is all right for you to be in the study. You do not have to join this study 
if you do not want to. If you do not, it will not affect anything at home or in your health care.  
You can quit the study at any time.  If you do decide to join, you will help us to help the people in 
this town protect themselves against Chagas’ disease. 
 
We will record your name and address, so that we can tell your parents/guardians the results of 
our tests. We will not give the results of your tests to anyone but you, your parent/guardian and 




Name of participant (print) 
 ________________________________________________ 
 




____________________________    ___/___/___ 




________________________________    ___/___/___ 




7 Appendix 2 Satellite Imagery 
 
Figure 11.  Satellite image of Peru showing Quequeña in the South of the country near Bolivia. 
 
Figure 12. Satelitte image showing location of Quequeña relative to Arequipa.  Arequipa lies at the 
base of an active volcano (snow capped peak, top). 
 50
 
Figure 13.  Satellite image of Quequeña illustrating the agricultural community in isolation. 
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